Conferences Attended

Event date: October 11th-15th, 2023

American Association for Cancer Research

Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors : Preventing deleterious ‘de-hinging’ to improve tolerability.